Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Immutep Limited is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases. The company operates within the biopharmaceutical and immuno-oncology industries, with its research centered on modulating the immune system through targeting the Lymphocyte Activation Gene-3 (LAG-3) pathway. Its primary value proposition is the development of first-in-class and best-in-class therapies that can enhance or suppress immune responses depending on the disease context.
The company’s core product candidate is eftilagimod alpha (efti), an antigen-presenting cell activator designed to stimulate immune responses in oncology settings, particularly in combination with immune checkpoint inhibitors. Immutep serves global pharmaceutical partners, clinical research institutions, and ultimately oncology and autoimmune patient populations. Founded in 1987 and originally operating under different corporate structures, the company evolved into its current form following a series of restructurings and strategic refocusing on LAG-3 biology, becoming publicly listed on the Australian Securities Exchange and later trading on U.S. over-the-counter markets.
Business Operations
Immutep’s operations are organized around its oncology and autoimmune disease development programs, both driven by proprietary LAG-3-related technologies. The company generates value primarily through clinical development, strategic collaborations, and licensing arrangements rather than commercial product sales, as its programs remain in clinical trial stages. Its lead oncology program evaluates eftilagimod alpha in combination with approved therapies across multiple solid tumor indications.
The company conducts research and development activities internationally, leveraging clinical trial sites across Europe, North America, and Australia. Immutep controls a portfolio of patents covering LAG-3 applications and maintains collaborative relationships with global pharmaceutical companies for combination trials. It operates through wholly owned subsidiaries, including Immutep S.A.S., which supports European research and development activities.
Strategic Position & Investments
Immutep’s strategy is focused on advancing its LAG-3 pipeline through mid- to late-stage clinical trials while positioning its assets for potential partnerships, licensing, or acquisition by larger pharmaceutical companies. Growth initiatives center on expanding combination therapy studies in immuno-oncology and selectively advancing autoimmune programs that address high unmet medical needs.
The company has invested heavily in clinical trials evaluating eftilagimod alpha in combination with immune checkpoint inhibitors and chemotherapy. In addition to its lead asset, Immutep maintains earlier-stage programs targeting autoimmune indications such as multiple sclerosis and inflammatory diseases. Data regarding additional material acquisitions or equity investments beyond internal pipeline development is inconclusive based on available public sources.
Geographic Footprint
Immutep is headquartered in Australia, with significant operational and research presence in Europe, particularly France, through its subsidiary Immutep S.A.S. The company maintains a global clinical trial footprint, with studies conducted across Europe, North America, and Australia, reflecting its international development strategy.
While Immutep does not operate commercial manufacturing facilities, it exerts international influence through partnerships, contract research organizations, and multinational clinical trial networks. Its investor base and market presence extend across the Asia-Pacific region, Europe, and the United States via public market listings.
Leadership & Governance
Immutep is led by an experienced management team with deep expertise in biotechnology, immunology, and global drug development. The leadership emphasizes scientific rigor, capital discipline, and strategic partnering to maximize the value of its clinical-stage assets.
Key executives include:
- Marc Voigt – Chief Executive Officer
- Frédéric Triebel – Chief Scientific Officer
- Paul Hopper – Non-Executive Chairman
- Rolf H. Swenson – Non-Executive Director
- Bruno Helwig – Chief Financial Officer